eif 4e full length Search Results


91
SignalChem 4e bp1
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
4e Bp1, supplied by SignalChem, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pmc03020721-142-27-33?v=SignalChem
Average 91 stars, based on 1 article reviews
4e bp1 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology full length eif4e
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Full Length Eif4e, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pmc03360453-47-50-52?v=Santa+Cruz+Biotechnology
Average 95 stars, based on 1 article reviews
full length eif4e - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

90
TA Instruments thermal solutions 1.4e software
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Thermal Solutions 1.4e Software, supplied by TA Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pmc03534896-151-15-18?v=TA+Instruments
Average 90 stars, based on 1 article reviews
thermal solutions 1.4e software - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
TA Instruments thermal solutions 1.4e
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Thermal Solutions 1.4e, supplied by TA Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pmc03534896-65-18-21?v=TA+Instruments
Average 90 stars, based on 1 article reviews
thermal solutions 1.4e - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

94
Shodex anion analysis column
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Anion Analysis Column, supplied by Shodex, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pm31152987-74-17-20?v=Shodex
Average 94 stars, based on 1 article reviews
anion analysis column - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

90
Sterling International Inc methyl (2e,4e,6z)-decatrienoate (mdt) lure
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Methyl (2e,4e,6z) Decatrienoate (Mdt) Lure, supplied by Sterling International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pm34850046-42-41-44?v=Sterling+International+Inc
Average 90 stars, based on 1 article reviews
methyl (2e,4e,6z)-decatrienoate (mdt) lure - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
TA Instruments 2910 modulated differential scanning calorimeter v4.4e
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
2910 Modulated Differential Scanning Calorimeter V4.4e, supplied by TA Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pm19819829-58-15-21?v=TA+Instruments
Average 90 stars, based on 1 article reviews
2910 modulated differential scanning calorimeter v4.4e - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

92
ChromaDex chromadex dodeca2e 4e 8z 10e z tetraenoic acid isobutylamide
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Chromadex Dodeca2e 4e 8z 10e Z Tetraenoic Acid Isobutylamide, supplied by ChromaDex, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pm39860258-339-18-18?v=ChromaDex
Average 92 stars, based on 1 article reviews
chromadex dodeca2e 4e 8z 10e z tetraenoic acid isobutylamide - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier

94
ChromaDex dodeca 2e 4e dienoic acid isobutylamide
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Dodeca 2e 4e Dienoic Acid Isobutylamide, supplied by ChromaDex, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pmc09659013-322-13-19?v=ChromaDex
Average 94 stars, based on 1 article reviews
dodeca 2e 4e dienoic acid isobutylamide - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

97
Shodex asahipak nh2 p50 4 e column
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Asahipak Nh2 P50 4 E Column, supplied by Shodex, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pm20056550-152-7-15?v=Shodex
Average 97 stars, based on 1 article reviews
asahipak nh2 p50 4 e column - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology p 4e bp1
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
P 4e Bp1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/pmc12683853-110-40-44?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
p 4e bp1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

91
ChromaDex compound dodeca 2e 4e dienoic acid isobutylamide
IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms <t>of</t> <t>4E-BP1</t> on Thr37/46 or against GAPDH (F), as indicated.
Compound Dodeca 2e 4e Dienoic Acid Isobutylamide, supplied by ChromaDex, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/eif+4e+full+length/10__1177_slash_1934578x1601100827-91-10-14?v=ChromaDex
Average 91 stars, based on 1 article reviews
compound dodeca 2e 4e dienoic acid isobutylamide - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

Image Search Results


IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms of 4E-BP1 on Thr37/46 or against GAPDH (F), as indicated.

Journal: The Journal of Biological Chemistry

Article Title: Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN? Signaling *

doi: 10.1074/jbc.M110.183566

Figure Lengend Snippet: IFNλ-dependent activation of ERK/RSK1 and mTOR signaling cascades in HT-29 cells. A–F, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. The cells were lysed, and total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies against the phosphorylated form of RSK1 on Thr359/Ser363 or against RSK1 (A); with antibodies against the phosphorylated forms of ERK on Thr202/Tyr204 or against ERK (B); with antibodies against the phosphorylated form of eIF4B on Ser422 or against eIF4B (C); with antibodies against the phosphorylated form of mTOR on Ser2448 or against GAPDH (D); with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K (E); or with antibodies against the phosphorylated forms of 4E-BP1 on Thr37/46 or against GAPDH (F), as indicated.

Article Snippet: SL0101-1 was used at a final concentration of 80 μ m , and BI-D1870 was used at a final concentration of 10 μ m . GST-4E-BP1, His-tagged 4E-BP1, and active PDK1 were from SignalChem (Richmond, Canada).

Techniques: Activation Assay, SDS Page

IFNλ-dependent activation of RSK1 and mTOR pathways in ARPE-19 cells. A–C, serum-starved ARPE-19 cells were pretreated with rapamycin or U0126 as indicated and then treated with IFNλ for the indicated times. Total cell lysates were resolved by SDS-PAGE and immunoblotted with anti-phospho-Thr359/Ser363 RSK1, anti-RSK1, anti-phospho-Ser422-eIF4B, or anti-eIF4B antibodies (A); with anti-phospho-Thr37/46-4E-BP1 or anti-GAPDH antibodies (B); or with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K or anti-GAPDH (C), as indicated.

Journal: The Journal of Biological Chemistry

Article Title: Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN? Signaling *

doi: 10.1074/jbc.M110.183566

Figure Lengend Snippet: IFNλ-dependent activation of RSK1 and mTOR pathways in ARPE-19 cells. A–C, serum-starved ARPE-19 cells were pretreated with rapamycin or U0126 as indicated and then treated with IFNλ for the indicated times. Total cell lysates were resolved by SDS-PAGE and immunoblotted with anti-phospho-Thr359/Ser363 RSK1, anti-RSK1, anti-phospho-Ser422-eIF4B, or anti-eIF4B antibodies (A); with anti-phospho-Thr37/46-4E-BP1 or anti-GAPDH antibodies (B); or with antibodies against the phosphorylated form of p70S6K on Thr421/Ser424 or against p70S6K or anti-GAPDH (C), as indicated.

Article Snippet: SL0101-1 was used at a final concentration of 80 μ m , and BI-D1870 was used at a final concentration of 10 μ m . GST-4E-BP1, His-tagged 4E-BP1, and active PDK1 were from SignalChem (Richmond, Canada).

Techniques: Activation Assay, SDS Page

Binding of 4E-BP1 and RSK1 to the 7-methylguanosine cap complex prevents recruitment of eIF4G, eIF4A, and eIF4E to the cap complex. A, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. Cell lysates were bound to the cap analog m7GTP conjugated to beads, and bound proteins were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. B, HT-29 cells were treated as indicated and assayed as described in A. Bound proteins were immunoblotted with the indicated antibodies. C, serum-starved HT-29 cells were pretreated for 6 h with SL0101-1 and were subsequently treated with IFNλ, as indicated. D, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and then treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. Equal amounts of cell lysates were immunoprecipitated (IP) with an anti-4E-BP1 antibody, and immune complexes were resolved by SDS-PAGE and immunoblotted with anti-RSK1 or anti-4E-BP1 antibodies, as indicated. E, HT-29 cells were pretreated for 6 h with SL0101-1 and were left untreated or treated with IFNλ, in the continuous presence or absence of inhibitor, as indicated. Equal amounts of cell lysates were immunoprecipitated with anti-4EBP1 antibodies, and immune complexes were resolved by SDS-PAGE for analysis of 4E-BP1 and RSK1, as indicated. F, HT-29 cells were transfected with either control siRNA or siRNA specifically targeting 4E-BP1 and treated with IFNλ, as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies, against 4E-BP1 or GAPDH, as indicated. G, cells were transfected with either control siRNA or siRNA specifically targeting 4E-BP1 and treated with IFNλ, as indicated. Cell lysates were bound to the cap analog m7GTP conjugated to beads, and bound proteins were resolved by SDS-PAGE and immunoblotted with the indicated antibodies.

Journal: The Journal of Biological Chemistry

Article Title: Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN? Signaling *

doi: 10.1074/jbc.M110.183566

Figure Lengend Snippet: Binding of 4E-BP1 and RSK1 to the 7-methylguanosine cap complex prevents recruitment of eIF4G, eIF4A, and eIF4E to the cap complex. A, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and were either left untreated or treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. Cell lysates were bound to the cap analog m7GTP conjugated to beads, and bound proteins were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. B, HT-29 cells were treated as indicated and assayed as described in A. Bound proteins were immunoblotted with the indicated antibodies. C, serum-starved HT-29 cells were pretreated for 6 h with SL0101-1 and were subsequently treated with IFNλ, as indicated. D, serum-starved HT-29 cells were pretreated for 60 min with U0126 or rapamycin and then treated with IFNλ, in the continuous presence or absence of rapamycin or U0126, as indicated. Equal amounts of cell lysates were immunoprecipitated (IP) with an anti-4E-BP1 antibody, and immune complexes were resolved by SDS-PAGE and immunoblotted with anti-RSK1 or anti-4E-BP1 antibodies, as indicated. E, HT-29 cells were pretreated for 6 h with SL0101-1 and were left untreated or treated with IFNλ, in the continuous presence or absence of inhibitor, as indicated. Equal amounts of cell lysates were immunoprecipitated with anti-4EBP1 antibodies, and immune complexes were resolved by SDS-PAGE for analysis of 4E-BP1 and RSK1, as indicated. F, HT-29 cells were transfected with either control siRNA or siRNA specifically targeting 4E-BP1 and treated with IFNλ, as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with antibodies, against 4E-BP1 or GAPDH, as indicated. G, cells were transfected with either control siRNA or siRNA specifically targeting 4E-BP1 and treated with IFNλ, as indicated. Cell lysates were bound to the cap analog m7GTP conjugated to beads, and bound proteins were resolved by SDS-PAGE and immunoblotted with the indicated antibodies.

Article Snippet: SL0101-1 was used at a final concentration of 80 μ m , and BI-D1870 was used at a final concentration of 10 μ m . GST-4E-BP1, His-tagged 4E-BP1, and active PDK1 were from SignalChem (Richmond, Canada).

Techniques: Binding Assay, SDS Page, Immunoprecipitation, Transfection

Binding of inactive RSK1 to 4E-BP1. A, equal amounts of GST-RSK1 or GST-RSK1 (activated) were annealed with 4E-BP1-His and then bound to the His affinity column. Equal amounts from fractions collected from the affinity column were resolved by SDS-PAGE and immunoblotted with antibodies against GST or 4E-BP1, as indicated. B, input protein levels from the experiment shown in A for GST-RSK1 (sample A) or GST-RSK1 activated (sample B). Immunoblotting with anti-GST or the anti-phospho-Ser221 RSK1 or anti-4E-BP1 (to detect His-4E-BP1) is shown. C, equal amounts of GST-RSK1 were subjected to in vitro kinase assays using active ERK1 and active PDK1, in the presence or absence of the SL0101-1 inhibitor, and then were annealed with 4E-BP1-His and bound to the His affinity column. After extensive washing, proteins were eluted from the column, and equal amounts from each eluted sample were resolved by SDS-PAGE and immunoblotted with antibodies against GST and 4E-BP1, as indicated. D, equal amounts of GST-RSK1 (activated) or GST-RSK1 (activated) that was subjected to an in vitro phosphatase (PP2A) assay were annealed with 4E-BP1-His. After binding to the His affinity column and extensive washing, proteins were eluted from the column, and equal amounts of eluted samples were resolved by SDS-PAGE and immunoblotted with antibodies against GST or 4E-BP1, as indicated. E, input protein levels from the experiment shown in D (panel A) for activated GST-RSK1 (sample A) or activated GST-RSK1 after subjected to in vitro phosphatase (PP2A) assay (sample B) or GST (sample C). Immunoblotting with anti-GST, anti-phospho-Ser221 RSK1 or anti-4E-BP1 (to detect 4E-BP1-His) is shown.

Journal: The Journal of Biological Chemistry

Article Title: Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN? Signaling *

doi: 10.1074/jbc.M110.183566

Figure Lengend Snippet: Binding of inactive RSK1 to 4E-BP1. A, equal amounts of GST-RSK1 or GST-RSK1 (activated) were annealed with 4E-BP1-His and then bound to the His affinity column. Equal amounts from fractions collected from the affinity column were resolved by SDS-PAGE and immunoblotted with antibodies against GST or 4E-BP1, as indicated. B, input protein levels from the experiment shown in A for GST-RSK1 (sample A) or GST-RSK1 activated (sample B). Immunoblotting with anti-GST or the anti-phospho-Ser221 RSK1 or anti-4E-BP1 (to detect His-4E-BP1) is shown. C, equal amounts of GST-RSK1 were subjected to in vitro kinase assays using active ERK1 and active PDK1, in the presence or absence of the SL0101-1 inhibitor, and then were annealed with 4E-BP1-His and bound to the His affinity column. After extensive washing, proteins were eluted from the column, and equal amounts from each eluted sample were resolved by SDS-PAGE and immunoblotted with antibodies against GST and 4E-BP1, as indicated. D, equal amounts of GST-RSK1 (activated) or GST-RSK1 (activated) that was subjected to an in vitro phosphatase (PP2A) assay were annealed with 4E-BP1-His. After binding to the His affinity column and extensive washing, proteins were eluted from the column, and equal amounts of eluted samples were resolved by SDS-PAGE and immunoblotted with antibodies against GST or 4E-BP1, as indicated. E, input protein levels from the experiment shown in D (panel A) for activated GST-RSK1 (sample A) or activated GST-RSK1 after subjected to in vitro phosphatase (PP2A) assay (sample B) or GST (sample C). Immunoblotting with anti-GST, anti-phospho-Ser221 RSK1 or anti-4E-BP1 (to detect 4E-BP1-His) is shown.

Article Snippet: SL0101-1 was used at a final concentration of 80 μ m , and BI-D1870 was used at a final concentration of 10 μ m . GST-4E-BP1, His-tagged 4E-BP1, and active PDK1 were from SignalChem (Richmond, Canada).

Techniques: Binding Assay, Affinity Column, SDS Page, Western Blot, In Vitro

RSK1 activity is required for IFNλ-dependent phosphorylation of 4E-BP1 on Thr37/46. A, serum-starved HT-29 cells were pretreated with SL0101-1 or diluent for 6 h and then treated with IFNλ for the indicated times, in the continuous presence or absence of SL0101-1, as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. Equal cell lysates from the same experiment were analyzed separately by SDS-PAGE and immunoblotted with an anti-phospho-RSK1 (Ser221) and anti-RSK1. B, HT29 cells were transfected with either control siRNA or siRNA targeting RSK1 and treated with IFNλ, as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. C, serum-starved HT-29 cells were pretreated with U0126 for 1 h and then treated with IFNλ for 90 min. The cells were lysed, and equal amounts of protein were immunoprecipitated (IP) with an anti-RSK1 antibody. In vitro kinase assays to detect RSK activity were subsequently carried out on the immunoprecipitates, using a 4E-BP1-His protein as an exogenous substrate. D, serum-starved HT-29 cells were pretreated with SL0101-1 for 6 h or BI-D1870 for 1 h and then treated with IFNλ for the indicated times. The cells were lysed, and equal amounts of protein were immunoprecipitated with an anti-RSK1 antibody. In vitro kinase assays to detect RSK activity were subsequently carried out on the immunoprecipitates, using a GST-4E-BP1 protein as an exogenous substrate.

Journal: The Journal of Biological Chemistry

Article Title: Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN? Signaling *

doi: 10.1074/jbc.M110.183566

Figure Lengend Snippet: RSK1 activity is required for IFNλ-dependent phosphorylation of 4E-BP1 on Thr37/46. A, serum-starved HT-29 cells were pretreated with SL0101-1 or diluent for 6 h and then treated with IFNλ for the indicated times, in the continuous presence or absence of SL0101-1, as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. Equal cell lysates from the same experiment were analyzed separately by SDS-PAGE and immunoblotted with an anti-phospho-RSK1 (Ser221) and anti-RSK1. B, HT29 cells were transfected with either control siRNA or siRNA targeting RSK1 and treated with IFNλ, as indicated. Total cell lysates were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. C, serum-starved HT-29 cells were pretreated with U0126 for 1 h and then treated with IFNλ for 90 min. The cells were lysed, and equal amounts of protein were immunoprecipitated (IP) with an anti-RSK1 antibody. In vitro kinase assays to detect RSK activity were subsequently carried out on the immunoprecipitates, using a 4E-BP1-His protein as an exogenous substrate. D, serum-starved HT-29 cells were pretreated with SL0101-1 for 6 h or BI-D1870 for 1 h and then treated with IFNλ for the indicated times. The cells were lysed, and equal amounts of protein were immunoprecipitated with an anti-RSK1 antibody. In vitro kinase assays to detect RSK activity were subsequently carried out on the immunoprecipitates, using a GST-4E-BP1 protein as an exogenous substrate.

Article Snippet: SL0101-1 was used at a final concentration of 80 μ m , and BI-D1870 was used at a final concentration of 10 μ m . GST-4E-BP1, His-tagged 4E-BP1, and active PDK1 were from SignalChem (Richmond, Canada).

Techniques: Activity Assay, SDS Page, Transfection, Immunoprecipitation, In Vitro

RSK1 associates with 4E-BP1 in the 7-methylguanosine cap complex. A, serum-starved 4E-BP1+/+ and 4E-BP1−/− cells were treated with mouse IFNα for the indicated times. Equal amounts of cell lysates were incubated with cap analog beads, and after intensive washing, the retained proteins were resolved by SDS-PAGE and immunoblotted with antibodies against RSK1, 4E-BP1, or eIF4E. B, total cell lysates from the same experiment shown in A were resolved by SDS-PAGE and immunoblotted with the indicated antibodies.

Journal: The Journal of Biological Chemistry

Article Title: Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN? Signaling *

doi: 10.1074/jbc.M110.183566

Figure Lengend Snippet: RSK1 associates with 4E-BP1 in the 7-methylguanosine cap complex. A, serum-starved 4E-BP1+/+ and 4E-BP1−/− cells were treated with mouse IFNα for the indicated times. Equal amounts of cell lysates were incubated with cap analog beads, and after intensive washing, the retained proteins were resolved by SDS-PAGE and immunoblotted with antibodies against RSK1, 4E-BP1, or eIF4E. B, total cell lysates from the same experiment shown in A were resolved by SDS-PAGE and immunoblotted with the indicated antibodies.

Article Snippet: SL0101-1 was used at a final concentration of 80 μ m , and BI-D1870 was used at a final concentration of 10 μ m . GST-4E-BP1, His-tagged 4E-BP1, and active PDK1 were from SignalChem (Richmond, Canada).

Techniques: Incubation, SDS Page